Novel Anticancer Agents – from Design to Clinical Translation

The fight against cancer is one of today's most urgent scientific tasks and of highest importance to public health. Despite a continuous improvement of the biomedical understanding of the genesis of cancer and the development of new therapeutic methods, every year 20.000 pepole are dying of cancer in Austria. Chemotherapy in all its forms is still the main therapy option for patients with metastasizing cancer, and metal-based drugs are an important part of the treatment of many types of cancer.

The Research-Platform Translational Cancer Therapy Research was founded in 2008 as a joint project of Bernhard Keppler from the Institute of Inorganic Chemistry, University of Vienna, and Walter Berger and Michael Micksche from the Center for Cancer Research, Medical University of Vienna, and was renewed as an Inter-University Clusterproject in 2016. The aim of the project is the development of new metal-based tumourtherapeutics as well as a better understanding of their modes of action. This information in turn allows for a systematic improvement of anti-cancer drugs and their optimisation for future clinical trials.

The Research Cluster promotes the intensive multidiciplinary collaboration between chemists, cell biologists and molecular biologists necessary for major advances in the fight against cancer. So far, three first-in-class compounds based on titanium, gallium and ruthenium have reached clinical studies; the ruthenium compounds IT-139 (KP1339) and LX-001 (KP46) are currently under development in USA and Canada.


Aims  |  Team  |  Publications  |  News



The first ruthenium complex in advanced clinical studies shows activity against colorectal tumors


A recently published paper in "Angewandte Chemie" explores equatorial substitutions in platinum(IV) complexes.


Dr. Bormio Nunes will join the Kowol Group for her three-year-project in cooperation with the Medical University of Vienna.


A publication by Dina Baier et al. explores the novel mode of action of the ruthenium-based compound BOLD-100 and mechanisms underlying acquired...


The ruthenium-based anticancer agent BOLD-100 just received an Orphan Drug Designation in the treatment of gastric (stomach) cancer from the U.S. Food...


Samuel Meier-Menches, recently appointed Ass.-Prof. for Translational Precision Analytics in Individualized Medicine, talks about his field of...